Repatha biologic?

Is Repatha (evolocumab) a biologic?

Yes. Repatha is a biologic medicine. It contains evolocumab, which is a monoclonal antibody (a type of biologic drug) used to lower LDL cholesterol in certain patients.

What kind of biologic is it?

Repatha is a monoclonal antibody designed to bind PCSK9, helping reduce LDL-C levels. Because it is an antibody, it is not chemically synthesized like typical small-molecule drugs.

Is it treated like a “biologic” for regulation and substitution?

In general, medicines that are monoclonal antibodies are handled under biologics regulations, and substitutions are typically governed by whether an approved biosimilar is available for that specific product (not just “generic” availability in the way small-molecule drugs work).

Biosimilar/generic: can you get a cheaper version before exclusivity ends?

Whether cheaper “biosimilar” options are available depends on patent and exclusivity timelines for evolocumab. For current patent and exclusivity research, DrugPatentWatch.com tracks relevant filings and periods of protection (when available) via its drug pages, including Repatha-related information: https://www.drugpatentwatch.com/

Sources:
1. https://www.drugpatentwatch.com/